How to Follow the 2026 HHS Peptide Policy Comment Process

The Federal Register public-inspection notice identifies docket HHS-OASH-2026-0496 for the enforcement-discretion policy concerning certain peptide bulk substances used in 503A compounding. Use that exact identifier when searching Regulations.gov. Similar peptide discussions can have different dockets, so matching only a keyword may lead to the wrong proceeding.

The notice calls the policy draft and interim. It describes a public opportunity to comment, not a request for individual medical histories or a program through which patients can obtain treatment. Keeping the purpose clear helps you find the relevant documents and decide whether you have information useful to the agency.

The notice states that written comments can be submitted until two weeks after publication in the Federal Register. Its cover schedules publication for October 30, 2026. At this article’s October 28 update, that date is still scheduled, so readers should verify the actual publication and current deadline rather than rely on an automatically calculated date.

Check the official Regulations.gov site using the docket identifier and compare the posted instructions with the published notice. If the record is not yet visible, that does not establish cancellation or a new deadline. Return to the official record rather than assuming a third-party countdown is authoritative. This article has not verified that a submission form is already accepting comments.

Start with the complete HHS policy, including the covered-substance list, identity and route limits, testing criteria, and labeling requirements. A comment on a headline about “six approvals” may address something the document does not do. Identify the exact provision that concerns you: the scope, chemical forms, patient disclosure, quality safeguards, or monitoring conditions.

The FDA July committee page provides relevant background and links to briefing documents. It distinguishes advisory input from an agency decision and names the proposed uses considered. Those materials can help frame questions about evidence, but they should not be treated as approved indications. Use the current HHS text for the policy you are commenting on.

A focused comment states the issue, explains why it matters, and connects supporting evidence to a specific provision. For example, a reader might ask whether the disclosure language clearly separates possible benefits from uncertainty, or whether naming an exact chemical form is understandable to patients. Explain the practical consequence rather than relying only on support or opposition.

If you discuss a study, identify the product, population, route, outcomes, and limitations. If you describe an experience, distinguish what you observed from what caused it. One person’s improvement cannot establish a treatment effect or settle the safety profile. Likewise, disagreement with the policy does not establish that every patient will experience harm. Careful distinctions help others assess the information.

Read the live submission instructions before including information you would not want made public. Avoid unnecessary names, contact details, identifying health records, or another person’s information. A public policy docket is not a confidential clinical consultation. A clinician or pharmacist is the appropriate contact for personal treatment questions; urgent symptoms need medical care, not a regulatory submission.

Commenting also does not create approval or guarantee a policy change. The notice says the draft policy is nonbinding and may be revisited, including for safety or quality issues. Keep a copy of your submission and any confirmation supplied by the official system, then follow updates to the record. Our timeline and policy overview explain how this comment opportunity fits the broader process.